At-Home Alzheimer's Test Uses Just a Finger Prick of Blood

Diagnosing Alzheimer's disease might soon be as simple as pricking your finger, collecting a few drops of blood, and dropping a test kit in the mail.

Researchers at the UK Dementia Research Institute's Biomarker Factory at UCL are working to turn this vision into reality. Their team is part of a global effort to develop and validate finger-prick blood tests that can detect Alzheimer's years before symptoms appear.

The tests work by identifying specific proteins in blood that signal disease. In Alzheimer's, abnormal proteins gradually build up in the brain, forming amyloid plaques and tau tangles that damage neural networks. These same proteins appear in blood long before memory problems start.

A recent study of 337 people showed that dried blood samples from finger pricks can detect Alzheimer's-related changes with about 86% accuracy compared to conventional methods. The samples remain stable without refrigeration, making them practical for mailing to labs.

Current diagnostic methods have significant drawbacks. PET scans are expensive, use radioactivity, and require specialized facilities. Spinal taps to extract cerebrospinal fluid are invasive and painful, and some patients can't have them done at all.

Cognitive tests have their own problems. They can misdiagnose people whose first language differs from the test language or who have other conditions affecting cognition. Traditional blood tests need immediate processing or refrigeration, making them impractical for large-scale screening, especially in rural areas.

The finger-prick alternative eliminates these barriers. People can complete the test at home without special equipment or training.

The Bright Side

The research team is tackling real challenges to make these tests widely available. They're experimenting with different detection methods using tiny blood volumes to improve sensitivity and reliability.

Beyond tau and amyloid, they're testing additional proteins associated with Alzheimer's and other conditions like Parkinson's disease and multiple sclerosis. This could help distinguish between different neurodegenerative diseases.

The biggest technical hurdle involves the biomarkers themselves. Alzheimer's protein levels are much lower in blood than in cerebrospinal fluid, requiring extremely sensitive measurement technology.

Researchers are also developing collection and mailing methods that keep proteins stable without refrigeration. Without proper handling, proteins can degrade and produce inaccurate readings.

Data interpretation adds another layer of complexity. Some people show high biomarker levels without disease symptoms, while others have low levels despite clear signs of illness.

The stakes are high because early detection could transform treatment. Novel therapies are emerging that may slow Alzheimer's progression, but they work best when started early, before irreversible brain damage occurs.

Once refined and validated, these tests could screen at-risk populations, track disease progression, and evaluate whether new treatments are working. They could bring affordable, accessible Alzheimer's screening to millions of people worldwide.